Buscopan

# buscopan ## Overview - **Classification**: Antispasmodic, Anticholinergic (Quaternary Ammonium Compound) - **Mechanism**: Selectively blocks muscarinic receptors in the smooth muscle of the gastrointestinal, biliary, and genitourinary tracts, reducing spasms. ## Primary Indications 1. **Abdominal Cramps/Spasms** - Relief of painful cramps associated with conditions like Irritable Bowel Syndrome (IBS), spastic dysmenorrhea. 2. **Biliary/Renal Colic** - Adjunctive treatment for acute spasms in the biliary or renal tracts. 3. **Diagnostic Procedures** - To reduce spasms and aid visualization during endoscopy or radiological procedures. ## Adult Dosing ### Standard Dosing **Abdominal Spasms/Cramps (Oral)** - **Dose**: **10-20 mg** - **Frequency**: 3-5 times daily (TID-QID) - **Route**: Oral - **Maximum**: **100 mg** per 24 hours **Acute Severe Spasms (Parenteral)** - **Dose**: **20 mg** - **Frequency**: May repeat every **30 minutes** if needed - **Route**: Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) - **Maximum**: **100 mg** per 24 hours ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment guidelines. Use with **caution** due to potential for accumulation and increased anticholinergic effects. - **Hepatic Impairment**: No specific dose adjustment guidelines. Use with **caution**. - **Elderly Patients**: Use with **caution** due to increased susceptibility to anticholinergic adverse effects (e.g., urinary retention, cognitive impairment, blurred vision). Start with lower doses. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Not recommended** - **Special Notes**: Risk of paralytic ileus and severe anticholinergic effects is high. Generally contraindicated. ### Infants (1-12 months) - **Dose**: **Not generally recommended** for routine use. - **Special Notes**: In acute, severe spasms, **0.3-0.6 mg/kg** (parenteral) may be considered under strict medical supervision. Maximum **20 mg** per 24 hours. Oral forms not typically used. ### Children (1-12 years) **Abdominal Spasms/Cramps (Oral)** - **Dose (6-12 years)**: **10 mg** - **Frequency**: 3 times daily (TID) - **Maximum**: **30 mg** per 24 hours. **Acute Severe Spasms (Parenteral)** - **Dose (1-12 years)**: **0.3-0.6 mg/kg** per dose - **Frequency**: May repeat every **30 minutes** if needed for acute spasms. - **Maximum**: **1.5 mg/kg** per 24 hours or **100 mg** total, whichever is less. Use with caution for children <6 years. ### Adolescents (13-18 years) - **Dose**: Follow **adult dosing** guidelines. - **Maximum**: **100 mg** per 24 hours. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to butylscopolamine or excipients. - **Absolute**: Glaucoma (angle-closure). - **Absolute**: Myasthenia Gravis. - **Absolute**: Mechanical stenoses of the GI tract (e.g., pyloric stenosis). - **Absolute**: Paralytic or obstructive ileus, megacolon. - **Absolute**: Prostatic hypertrophy with urinary retention. - **Absolute**: Tachyarrhythmia. - **Relative**: Conditions predisposing to tachycardia (e.g., thyrotoxicosis, heart failure). ### Common Adverse Effects - **Common (1-10%)**: Dry mouth, blurred vision, tachycardia, dizziness, constipation, urinary retention. - **Serious but Rare**: Anaphylactic shock (especially with IV administration), severe skin reactions, paradoxical excitation (in some children). ### Key Drug Interactions - **Anticholinergics (e.g., TCAs, Antihistamines, Quinidine)**: Potentiated anticholinergic effects; monitor for increased dry mouth, urinary retention, blurred vision. - **Dopamine Antagonists (e.g., Metoclopramide)**: Reduced GI motility effect of both drugs; avoid concurrent use if aiming for prokinetic effect. - **Beta-agonists**: May increase risk of tachycardia; monitor heart rate. - **Antacids**: May reduce absorption of oral Buscopan if administered concurrently; separate administration by 1-2 hours. ## Monitoring & Follow-up - **Before Treatment**: Assess for contraindications (e.g., history of glaucoma, urinary retention, cardiac arrhythmias). - **During Treatment**: Monitor for resolution of spasm symptoms. - **Clinical Signs**: Watch for signs of urinary retention (difficulty voiding, abdominal discomfort), blurred vision, worsening constipation, or severe tachycardia. Seek immediate medical attention for severe abdominal pain, fever, nausea/vomiting, or bloody stools. ## Clinical Pearls - 💡 **Onset of Action**: Oral Buscopan typically takes 15-30 minutes to work. IV administration works within minutes for acute spasms. - 💡 **Not for Chronic Use**: Primarily for symptomatic relief of acute or intermittent spasms; not a treatment for underlying chronic conditions. - 💡 **Hydration**: Advise patients to stay well-hydrated to help manage dry mouth. - 💡 **Driving**: Warn patients about potential blurred vision and dizziness, which may impair ability to drive or operate machinery. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.